Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 37

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Acute respiratory distress syndrome

Recruiting

Study on [68Ga]FAPI-46 to Detect Fibroblast Activity in Patients with Non-Resolving Acute Respiratory Distress Syndrome (ARDS) in the ICU

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Universitair Medisch Centrum Groningen

Pulmonary embolism

Recruiting

Study on Treatments for Intermediate High-Risk Pulmonary Embolism: Comparing Percutaneous Embolectomy, Ultrasound-Assisted Thrombolysis with Alteplase, and Heparin

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Region Hovedstaden

Pulmonary tuberculosis

Recruiting

Study of cysteamine combined with standard tuberculosis treatment in adults with pulmonary tuberculosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Mercaptamine
  • Sponsor:National Institute For Infectious Diseases Lazzaro Spallanzani

Asthma

Recruiting

Study on Salbutamol and Ipratropium Bromide for Treating Moderate Asthma Attacks in Children

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Ipratropium Bromide Monohydrate
  • Sponsor:Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus

Non-small cell lung cancer

Recruiting

Study on the Safety of Tremelimumab Injections for Early-Stage Non-Small Cell Lung Cancer Patients

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Amsterdam UMC Stichting

Bronchopulmonary aspergillosis

Recruiting

Study Comparing Itraconazole and Nebulised Amphotericin B with Itraconazole Alone for Patients with Chronic Pulmonary Aspergillosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Itraconazole
  • Sponsor:Centre Hospitalier Universitaire De Poitiers

H1N1 influenza

Recruiting

Study on the Effects of Dexamethasone and Oseltamivir in Patients with Severe Influenza

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Oseltamivir
  • Sponsor:Fundacion De La Comunitat Valenciana Para La Gestion Del Instituto De Investigacion Sanitaria Y Biomedica De Alicante

Non-small cell lung cancer stage IV

Recruiting

Study on Maintenance Treatment with Pembrolizumab and Pemetrexed for Stage IV Non-Small Cell Lung Cancer Patients After Initial Chemotherapy and Immunotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Non-small cell lung cancer

Recruiting

Study on Imaging Non-Small Cell Lung Cancer Using 68GaNOTA-Anti-MMR VHH2 in Patients

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nanobody Against Macrophage Mannose Receptor, Conjugated With 1,4,7-Triazacyclononane-N,N',N''-Triacetic Acid, Labelled With Gallium Ga-68
  • Sponsor:UZ Brussel

Pulmonary sarcoidosis

Recruiting

Study of hydroxychloroquine with low-dose corticosteroids compared to medium-dose corticosteroids in patients with pulmonary sarcoidosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer

Recruiting

Study on Durvalumab and Radiotherapy for Patients with Early-Stage Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Amsterdam UMC Stichting

Small cell lung cancer extensive stage+1

Recruiting

Study of Durvalumab, Cisplatin, Carboplatin, and Etoposide for Patients with Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Universitaet Des Saarlandes

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.